Atrioventricular septal defect prevention: Difference between revisions
| Line 13: | Line 13: | ||
|- | |- | ||
| bgcolor="LightCoral"|<nowiki>"</nowiki>'''1.''' Prophylaxis against IE is not recommended for nondental procedures (such as esophagogastroduodenoscopy | | bgcolor="LightCoral"|<nowiki>"</nowiki>'''1.''' Prophylaxis against IE is not recommended for nondental procedures (such as esophagogastroduodenoscopy | ||
or colonoscopy) in the absence of active infection. (Level of Evidence: C) <nowiki>"</nowiki> | or colonoscopy) in the absence of active infection.''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])'' <nowiki>"</nowiki> | ||
|} | |} | ||
| Line 25: | Line 25: | ||
for adverse outcome from IE, including those with the following indications: | for adverse outcome from IE, including those with the following indications: | ||
a. Prosthetic cardiac valve or prosthetic material usedfor cardiac valve repair. (Level of Evidence: B) | a. Prosthetic cardiac valve or prosthetic material usedfor cardiac valve repair. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])'' | ||
b. Previous IE. (Level of Evidence: B) | b. Previous IE. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])'' | ||
c. Unrepaired and palliated cyanotic CHD, including surgically constructed palliative shunts and conduits. | c. Unrepaired and palliated cyanotic CHD, including surgically constructed palliative shunts and conduits. | ||
(Level of Evidence: B) | ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]]) | ||
d. Completely repaired CHD with prosthetic materials, whether placed by surgery or by catheter intervention, during the first 6 months after the procedure. (Level of Evidence: B) | d. Completely repaired CHD with prosthetic materials, whether placed by surgery or by catheter intervention, during the first 6 months after the procedure.([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]]) | ||
e. Repaired CHD with residual defects at the site or adjacent to the site of a prosthetic patch or prosthetic device that inhibit endothelialization. (Level of Evidence: B) | e. Repaired CHD with residual defects at the site or adjacent to the site of a prosthetic patch or prosthetic device that inhibit endothelialization. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]]) | ||
|- | |- | ||
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''2.''' It is reasonable to consider antibiotic prophylaxis against IE before vaginal delivery at the time of membrane rupture in select patients with the highest risk of adverse outcomes. This includes patients with | | bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''2.''' It is reasonable to consider antibiotic prophylaxis against IE before vaginal delivery at the time of membrane rupture in select patients with the highest risk of adverse outcomes. This includes patients with | ||
the following indications: | the following indications: | ||
a. Prosthetic cardiac valve or prosthetic material used for cardiac valve repair. (Level of Evidence: | a. Prosthetic cardiac valve or prosthetic material used for cardiac valve repair. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]]) | ||
b. Unrepaired and palliated cyanotic CHD, including surgically constructed palliative shunts and conduits. (Level of Evidence: C)'' <nowiki>"</nowiki> | b. Unrepaired and palliated cyanotic CHD, including surgically constructed palliative shunts and conduits. (Level of Evidence: C)'' <nowiki>"</nowiki> | ||
Revision as of 14:05, 3 October 2012
|
Atrioventricular septal defect Microchapters |
|
Differentiating Atrioventricular septal defect from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Atrioventricular septal defect prevention On the Web |
|
American Roentgen Ray Society Images of Atrioventricular septal defect prevention |
|
Risk calculators and risk factors for Atrioventricular septal defect prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Prevention
ACC / AHA Guidelines- Recommendations for Endocarditis Prophylaxis (DO NOT EDIT)
| Class III (Harm) |
| "1. Prophylaxis against IE is not recommended for nondental procedures (such as esophagogastroduodenoscopy
or colonoscopy) in the absence of active infection.(Level of Evidence: C) " |
| Class IIa |
| "1. Antibiotic prophylaxis before dental procedures that involve manipulation of gingival tissue or the periapical
region of teeth or perforation of the oral mucosa is reasonable in patients with CHD with the highest risk for adverse outcome from IE, including those with the following indications: a. Prosthetic cardiac valve or prosthetic material usedfor cardiac valve repair. (Level of Evidence: B) b. Previous IE. (Level of Evidence: B) c. Unrepaired and palliated cyanotic CHD, including surgically constructed palliative shunts and conduits. (Level of Evidence: B) d. Completely repaired CHD with prosthetic materials, whether placed by surgery or by catheter intervention, during the first 6 months after the procedure.(Level of Evidence: B) e. Repaired CHD with residual defects at the site or adjacent to the site of a prosthetic patch or prosthetic device that inhibit endothelialization. (Level of Evidence: B) |
| "2. It is reasonable to consider antibiotic prophylaxis against IE before vaginal delivery at the time of membrane rupture in select patients with the highest risk of adverse outcomes. This includes patients with
the following indications: a. Prosthetic cardiac valve or prosthetic material used for cardiac valve repair. (Level of Evidence: B) b. Unrepaired and palliated cyanotic CHD, including surgically constructed palliative shunts and conduits. (Level of Evidence: C) " |